Related Experiment Video
Updated: Jul 16, 2026
Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue (FACS-RTT) to Determine the Cellular Origin of Radioactive Signal
Published on: September 10, 2021
Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET
Anders Johansson1, Henry Engler, Gunnar Blomquist
1Department of Neurology, University Hospital, S-751 85 Uppsala, Sweden. anders.johansson@neurologi.uu.se
Objective:
To use deuterium-substituted [11C](L)-deprenyl PET to depict astrocytosis in vivo in patients with amyotrophic lateral sclerosis (ALS).
Background:
In human brain, the enzyme MAO-B is primarily located in astrocytes. L-deprenyl binds to MAO-B and autoradiography with 3H-L-deprenyl has been used to map astrocytosis in vitro. Motor neuron loss in ALS is accompanied by astrocytosis and astrocytes may play an active role in the neurodegenerative process. Deuterium-substituted [11C](L)-deprenyl PET provides an opportunity to localize astrocytosis in vivo in the brain of patients with ALS.
Methods:
Deuterium-substituted [11C](L)-deprenyl PET was performed in seven patients with ALS and seven healthy control subjects.
Results:
Increased uptake rate of [11C](L)-deprenyl was demonstrated in ALS in pons and white matter.
Conclusion:
This study provides evidence that astrocytosis may be detected in vivo in ALS by the use of deuterium-substituted [11C](L)-deprenyl PET though further studies are needed to determine whether deuterium-substituted [11C](L)-deprenyl binding tracks disease progression and reflects astrocytosis.
